Diabetes and diabetic complications
Lilly - Metabolic diseases
In January 2022, Evotec announced a drug discovery collaboration with Lilly in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation.
In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US$ 1 bn.
Chinook Therapeutics - Kidney disease
In March 2021, Evotec and Chinook Therapeutics announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines.
Under the terms of the agreement, Chinook and Evotec will share drug discovery and pre-clinical development responsibilities. Chinook will be responsible for clinical development and commercialisation of product candidates developed under the collaboration. Evotec will receive an undisclosed upfront payment, research funding, and will be eligible to receive progress-dependent milestone payments and tiered royalties on net sales for targets identified through the collaboration.
Novo Nordisk - Kidney disease
In August 2020, Evotec and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.
Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of thousands of chronic kidney disease patients. The collaboration intends to pursue the most relevant human disease biology in a therapeutic modality-agnostic approach to develop first-in-class therapeutics for patients suffering from CKD.
Under the terms of the agreement, Evotec and Novo Nordisk will share responsibilities during drug discovery and pre-clinical development. Novo Nordisk will be responsible for the clinical development and commercialisation of the products. Evotec will receive an undisclosed upfront payment, research funding and milestone potential of more than € 150 m per product as well as tiered royalties on net sales.
In September 2016, Evotec announced that Evotec and Bayer have entered into a five-year, multi-target research partnership. The goal is the development of multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during pre-clinical development of potential clinical candidates.
Under the terms of the agreement, Bayer received exclusive access to selected candidates as well as to Evotec’s CureNephron target pipeline. Bayer will be responsible for any subsequent clinical development and commercialisation. Evotec will receive a minimum of € 14 m over the contract period including research payments and an undisclosed licence fee. In addition, Evotec is eligible to receive pre-clinical, clinical and sales milestones of potentially over € 300 m as well as tiered royalties of up to low double-digit percentage of net sales.